CD8A and cholangiocarcinoma: Furthermore, in an orthotopic CCA model, Aurkine 16 significantly reduced tumor volumes compared to controls (Fig. 7F–H), along with an increase in p-H2AX+ cells (Fig. 7I) and enhanced infiltration of CD8+ and CD4+ T cells into tumors (Fig. 7J).